X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement aims to evaluate BAN2802, a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Alzheimer drug candidate.
Lead Product(s): BAN2802
Therapeutic Area: Neurology Product Name: BAN2802
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eisai Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 20, 2024
Details:
Leqembi (lecanemab-irmb) is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). It is being evaluated as IV maintenance dosing for the treatment of early Alzheimer's disease.
Lead Product(s): Lecanemab
Therapeutic Area: Neurology Product Name: Leqembi
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2024
Details:
Leqembi (lecanemab-irmb) is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). It is indicated for the treatment of Alzheimer’s disease.
Lead Product(s): Lecanemab-irmb
Therapeutic Area: Neurology Product Name: Leqembi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
Leqembi (lecanemab-irmb) is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). It is indicated for the treatment of Alzheimer’s disease.
Lead Product(s): Lecanemab-irmb
Therapeutic Area: Neurology Product Name: Leqembi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2023
Details:
Lecanemab is an investigational humanized monoclonal antibody for AD. Lecanemab selectively binds and eliminates soluble, toxic amyloid-beta (Aβ) aggregates (protofibrils) that are thought to contribute to the neurotoxicity in AD.
Lead Product(s): Lecanemab
Therapeutic Area: Neurology Product Name: BAN2401
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2022
Details:
The PD-BT2238 project is a second-generation alpha-synuclein antibody, combining an oligomer-selective alpha-synuclein antibody with BioArctic's Brain Transporter technology, designed to improve brain exposure.
Lead Product(s): PD-BT2238
Therapeutic Area: Neurology Product Name: PD-BT2238
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
Blood-brain barrier protects brain from foreign substances by restricting passage of these substances into brain. The patented technologyhas been developed to facilitate the transport of biopharmaceuticals across this barrier, thereby potentially improving drug efficacy.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
Lecanemab (BAN2401) is an investigational humanized monoclonal antibody for Alzheimer's disease selectively binds to neutralize and eliminate soluble, toxic amyloid-beta (Aβ) aggregates (protofibrils) that are thought to contribute to the neurodegenerative process in AD.
Lead Product(s): Lecanemab
Therapeutic Area: Neurology Product Name: BAN2401
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Details:
The granted substance patent focuses on the monoclonal antibody ABBV-0805, which selectively binds to and eliminates pathological aggregated forms called oligomers and protofibrils while sparing the physiological monomer form of alpha-synuclein.
Lead Product(s): ABBV-0805
Therapeutic Area: Neurology Product Name: ABBV-0805
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2022
Details:
AbbVie has been managing and funding the clinical development of ABBV-0805. The scope of the drug candidate ABBV-0805 may be broadened to include, for example, Lewy body dementia and multiple system atrophy.
Lead Product(s): ABBV-0805
Therapeutic Area: Neurology Product Name: ABBV-0805
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $755.0 million Upfront Cash: $80.0 million
Deal Type: Termination April 20, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
